“Patients suffering from Alzheimer’s disease (AD) exhibit a decline in cognitive abilities including an inability to recognise familiar faces…
The non-psychoactive phytocannabinoid cannabidiol (CBD) exerts neuroprotective, anti-oxidant and anti-inflammatory effects and promotes neurogenesis. CBD also reverses Aβ-induced spatial memory deficits in rodents.
This is the first study to investigate the effect of chronic CBD treatment on cognition in an AD transgenic mouse model.
Our findings suggest that CBD may have therapeutic potential for specific cognitive impairments associated with AD.”